Articles avec mandats d'accès public - Dennis E. KyleEn savoir plus
Non disponibles : 3
Quinolone-3-diarylethers: a new class of antimalarial drug
A Nilsen, AN LaCrue, KL White, IP Forquer, RM Cross, J Marfurt, ...
Science translational medicine 5 (177), 177ra37-177ra37, 2013
Exigences : US National Institutes of Health
Norselic Acids A−E, Highly Oxidized Anti-infective Steroids that Deter Mesograzer Predation, from the Antarctic Sponge Crella sp.
WS Ma, T Mutka, B Vesley, MO Amsler, JB McClintock, CD Amsler, ...
Journal of natural products 72 (10), 1842-1846, 2009
Exigences : US National Institutes of Health
Transition-metal-free one-pot tandem synthesis of 4-quinolone and 4H-thiochromen-4-one derivatives through sequential nucleophilic addition–elimination–SNAr reaction
D Wang, P Sun, P Jia, J Peng, Y Yue, C Chen
Synthesis 49 (18), 4309-4320, 2017
Exigences : National Natural Science Foundation of China
Disponibles quelque part : 112
Malaria: progress, perils, and prospects for eradication
BM Greenwood, DA Fidock, DE Kyle, SHI Kappe, PL Alonso, FH Collins, ...
The Journal of clinical investigation 118 (4), 1266-1276, 2008
Exigences : US National Institutes of Health
A novel multiple-stage antimalarial agent that inhibits protein synthesis
B Baragaña, I Hallyburton, MCS Lee, NR Norcross, R Grimaldi, TD Otto, ...
Nature 522 (7556), 315-320, 2015
Exigences : Bill & Melinda Gates Foundation, US National Institutes of Health, UK …
Open source drug discovery with the malaria box compound collection for neglected diseases and beyond
WC Van Voorhis, JH Adams, R Adelfio, V Ahyong, MH Akabas, P Alano, ...
PLoS pathogens 12 (7), e1005763, 2016
Exigences : US National Science Foundation, Bill & Melinda Gates Foundation, US National …
Artemisinin-Induced Dormancy in Plasmodium falciparum: Duration, Recovery Rates, and Implications in Treatment Failure
F Teuscher, ML Gatton, N Chen, J Peters, DE Kyle, Q Cheng
The Journal of infectious diseases 202 (9), 1362-1368, 2010
Exigences : US National Institutes of Health
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
MB Jiménez-Díaz, D Ebert, Y Salinas, A Pradhan, AM Lehane, ...
Proceedings of the National Academy of Sciences 111 (50), E5455-E5462, 2014
Exigences : US National Institutes of Health, Howard Hughes Medical Institute, National …
Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A
RG Linington, BR Clark, EE Trimble, A Almanza, LD Ureña, DE Kyle, ...
Journal of natural products 72 (1), 14-17, 2009
Exigences : US National Institutes of Health
A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum
A Roth, SP Maher, AJ Conway, R Ubalee, V Chaumeau, C Andolina, ...
Nature communications 9 (1), 1837, 2018
Exigences : Bill & Melinda Gates Foundation, US National Institutes of Health, Wellcome …
Role of pfmdr1 Amplification and Expression in Induction of Resistance to Artemisinin Derivatives in Plasmodium falciparum
M Chavchich, L Gerena, J Peters, N Chen, Q Cheng, DE Kyle
Antimicrobial Agents and Chemotherapy 54 (6), 2455-2464, 2010
Exigences : US National Institutes of Health
Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes
A Hott, D Casandra, KN Sparks, LC Morton, GG Castanares, A Rutter, ...
Antimicrobial agents and chemotherapy 59 (6), 3156-3167, 2015
Exigences : Bill & Melinda Gates Foundation, US National Institutes of Health
Artemisinin resistance in Plasmodium falciparum: a process linked to dormancy?
Q Cheng, DE Kyle, ML Gatton
International journal for parasitology: drugs and drug resistance 2, 249-255, 2012
Exigences : US National Institutes of Health, National Health and Medical Research …
Dragonamide E, a Modified Linear Lipopeptide from Lyngbya majuscula with Antileishmanial Activity
MJ Balunas, RG Linington, K Tidgewell, AM Fenner, LD Ureña, GD Togna, ...
Journal of natural products 73 (1), 60-66, 2010
Exigences : US National Institutes of Health
Protozoan persister-like cells and drug treatment failure
MP Barrett, DE Kyle, LD Sibley, JB Radke, RL Tarleton
Nature Reviews Microbiology 17 (10), 607-620, 2019
Exigences : US National Institutes of Health, UK Biotechnology and Biological Sciences …
Almiramides A− C: Discovery and development of a new class of leishmaniasis lead compounds
LM Sanchez, D Lopez, BA Vesely, G Della Togna, WH Gerwick, DE Kyle, ...
Journal of medicinal chemistry 53 (10), 4187-4197, 2010
Exigences : US National Institutes of Health
Epigenetic Tailoring for the Production of Anti-Infective Cytosporones from the Marine Fungus Leucostoma persoonii
J Beau, N Mahid, WN Burda, L Harrington, LN Shaw, T Mutka, DE Kyle, ...
Marine Drugs 10 (4), 762-774, 2012
Exigences : US National Institutes of Health
Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis
B Baragaña, B Forte, R Choi, S Nakazawa Hewitt, JA Bueren-Calabuig, ...
Proceedings of the National Academy of Sciences 116 (14), 7015-7020, 2019
Exigences : US Department of Energy, Bill & Melinda Gates Foundation, US National …
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials
Y Antonova-Koch, S Meister, M Abraham, MR Luth, S Ottilie, AK Lukens, ...
Science 362 (6419), eaat9446, 2018
Exigences : Bill & Melinda Gates Foundation, US National Institutes of Health, US Agency …
Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure
A Codd, F Teuscher, DE Kyle, Q Cheng, ML Gatton
Malaria journal 10, 1-6, 2011
Exigences : US National Institutes of Health
Les informations concernant la publication et le financement sont déterminées automatiquement par un programme informatique